Congenica is a spin-out from the Wellcome Trust Sanger Institute and a leading developer of clinical genomics software for inherited diseases.
Congenica’s Sapientia technology is able to screen whole genome sequence data to identify gene mutations and highlight those associated with inherited and acquired genetic disorders. It aims to revolutionise personalised patient care through accurate diagnoses, curation of evolving knowledge bases, and support in clinical trials and drug development.
In April 2019 Congenica announced that it ha raised an additional £13.25 million to hoist its completed Series B round to £23.3m. Parkwalk Advisors led the fresh fundraise and the round attracted new strategic investors, including Digital China Health Technologies Corporation Limited (DCHealth), alongside follow-on funding from existing investors Cambridge Innovation Capital plc and Amadeus Capital Partners.
Congenica was awarded a multi-year contract in 2019 to be the exclusive provider of diagnostic decision support services for the world-leading NHS Genomic Medicine Service.